The Vehicle, Fall 2007

Table of Contents Is This Thing On?Nichole D\u27Antoniopage 1 Death Came KnockingJacob Dawsonpage 5 Awaiting DecemberRebecca Griffithpage 9 ginamarieElizabeth Hoodpage 11 She LongsJennifer O\u27Neilpage 12 ForgottenStephanie Drozdpage 13 Art House WomanGreg Harrellpage 14 Young Woman OlderAmanda Vealepage 15 FirstRebecca Griffithpage 17 FlowJacob Dawsonpage 19 Am Animal AwareDanielle Meyerpage 20 Geneva 04\u27Stephanie Guyerpage 21 Poland, 1942.Jennifer O\u27Neilpage 22 Witness to the Atrophy of ForestsDanielle Meyerpage 23 Helvellyn IJacob Fosterpage 24 Three Out of Five Ain\u27t BadThomas McElweepage 25 FarceAmanda Vealepage 31 Strength of EmotionJennifer O\u27Neilpage 32 About the Authors Art Submissions Prerequisite for a RequiemJenna Smithcover Girl 3Jenna Smithpage 14 ManJenna Smithpage 16 Give Peace a ChanceMegan Mathypage 16 GraceJennifer O\u27Neilpage 20 Oh, the Places You\u27ll Go!Megan Mathypage 23https://thekeep.eiu.edu/vehicle/1086/thumbnail.jp

The Vehicle, Fall 2007

Table of Contents Is This Thing On?Nichole D\u27Antoniopage 1 Death Came KnockingJacob Dawsonpage 5 Awaiting DecemberRebecca Griffithpage 9 ginamarieElizabeth Hoodpage 11 She LongsJennifer O\u27Neilpage 12 ForgottenStephanie Drozdpage 13 Art House WomanGreg Harrellpage 14 Young Woman OlderAmanda Vealepage 15 FirstRebecca Griffithpage 17 FlowJacob Dawsonpage 19 Am Animal AwareDanielle Meyerpage 20 Geneva 04\u27Stephanie Guyerpage 21 Poland, 1942.Jennifer O\u27Neilpage 22 Witness to the Atrophy of ForestsDanielle Meyerpage 23 Helvellyn IJacob Fosterpage 24 Three Out of Five Ain\u27t BadThomas McElweepage 25 FarceAmanda Vealepage 31 Strength of EmotionJennifer O\u27Neilpage 32 About the Authors Art Submissions Prerequisite for a RequiemJenna Smithcover Girl 3Jenna Smithpage 14 ManJenna Smithpage 16 Give Peace a ChanceMegan Mathypage 16 GraceJennifer O\u27Neilpage 20 Oh, the Places You\u27ll Go!Megan Mathypage 23https://thekeep.eiu.edu/vehicle/1086/thumbnail.jp

The Vehicle, Spring 2008

Table of Contents Not So Hot Cocoa (To a fish named Mooshu)Gina Lobiancopage 1 LessonsGlen Davispage 2 Christian Campus HouseJacob Fosterpage 4 Gray AreaRebecca Griffithpage 5 Gathering RosebudsJacob Fosterpage 6 Play Those BluesJacob Dawsonpage 8 The Apple CarAmanda Vealepage 10 A Night at the UptownerJacob Fosterpage 12 Candy DishAnthony Hesseldenzpage 14 Winter DayAnna-Elise Pricepage 15 The Friendly FogSarah Ruhollpage 16 Hey MamaJacob Dawsonpage 18 Keep TurningStephanie Drozdpage 20 A Pen, A Rose, and a Bottle of JackCarissa Haydenpage 21 Ten Days LaterAndrew Deckerpage 22 FearShannara Holderpage 27 Thank You and GoodnightJacob Fosterpage 28 My Mother\u27s PassingAmanda Vealepage 30 The Bearded ManAndrew Deckerpage 32 TabooMario Podeschipage 34 DervishScott Lutzpage 41 IckJacob Fosterpage 42 Meditation of the SeasonsStephanie Drozdpage 45 Full MoonAnna-Elise Pricepage 47 Becoming WiseAmanda Vealepage 48 In SightAnthony Hesseldenzpage 50 About the Authors Art Submissions Down the TracksShannara Holdercovers and page 23 Out the Back DoorShannara Holderpage 24 UntitledJennifer O\u27Neilpage 25 LullabyShannara Holderpage 26https://thekeep.eiu.edu/vehicle/1089/thumbnail.jp

Efficacy and cost-effectiveness of a web-based and mobile stress-management intervention for employees: design of a randomized controlled trial

Background: Work-related stress is associated with a variety of mental and emotional problems and can lead to substantial economic costs due to lost productivity, absenteeism or the inability to work. There is a considerable amount of evidence on the effectiveness of traditional face-to-face stress-management interventions for employees; however, they are often costly, time-consuming, and characterized by a high access threshold. Web-based interventions may overcome some of these problems yet the evidence in this field is scarce. This paper describes the protocol for a study that will examine the efficacy and cost-effectiveness of a web-based guided stress-management training which is based on problem solving and emotion regulation and aimed at reducing stress in adult employees. Methods. The study will target stressed employees aged 18 and older. A randomized controlled trial (RCT) design will be applied. Based on a power calculation of d=.35 (1-β of 80%, α =.05), 264 participants will be recruited and randomly assigned to either the intervention group or a six-month waitlist control group. Inclusion criteria include an elevated stress level (Cohen's Perceived Stress Scale-10 ≥ 22) and current employment. Exclusion criteria include risk of suicide or previously diagnosed psychosis or dissociative symptoms. The primary outcome will be perceived stress, and secondary outcomes include depression and anxiety. Data will be collected at baseline and seven weeks and six months after randomization. An extended follow up at 12 months is planned for the intervention group. Moreover, a cost-effectiveness analysis will be conducted from a societal perspective and will include both direct and indirect health care costs. Data will be analyzed on an intention-to-treat basis and per protocol. Discussion. The substantial negative consequences of work-related stress emphasize the necessity for effective stress-management trainings. If the proposed internet intervention proves to be (cost-) effective, a preventative, economical stress-management tool will be conceivable. The strengths and limitations of the present study are discussed. Trial registration. German Register of Clinical Studies (DRKS): DRKS00004749. © 2013 Heber et al.; licensee BioMed Central Ltd

The Vehicle, Spring 2008

Table of Contents Not So Hot Cocoa (To a fish named Mooshu)Gina Lobiancopage 1 LessonsGlen Davispage 2 Christian Campus HouseJacob Fosterpage 4 Gray AreaRebecca Griffithpage 5 Gathering RosebudsJacob Fosterpage 6 Play Those BluesJacob Dawsonpage 8 The Apple CarAmanda Vealepage 10 A Night at the UptownerJacob Fosterpage 12 Candy DishAnthony Hesseldenzpage 14 Winter DayAnna-Elise Pricepage 15 The Friendly FogSarah Ruhollpage 16 Hey MamaJacob Dawsonpage 18 Keep TurningStephanie Drozdpage 20 A Pen, A Rose, and a Bottle of JackCarissa Haydenpage 21 Ten Days LaterAndrew Deckerpage 22 FearShannara Holderpage 27 Thank You and GoodnightJacob Fosterpage 28 My Mother\u27s PassingAmanda Vealepage 30 The Bearded ManAndrew Deckerpage 32 TabooMario Podeschipage 34 DervishScott Lutzpage 41 IckJacob Fosterpage 42 Meditation of the SeasonsStephanie Drozdpage 45 Full MoonAnna-Elise Pricepage 47 Becoming WiseAmanda Vealepage 48 In SightAnthony Hesseldenzpage 50 About the Authors Art Submissions Down the TracksShannara Holdercovers and page 23 Out the Back DoorShannara Holderpage 24 UntitledJennifer O\u27Neilpage 25 LullabyShannara Holderpage 26https://thekeep.eiu.edu/vehicle/1089/thumbnail.jp

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk